Therapeutic Targeting of Integrin αvβ6 in Breast Cancer

Article English OPEN
Moore, Kate M. ; Thomas, Gareth J. ; Duffy, Stephen W. ; Warwick, Jane ; Gabe, Rhian ; Chou, Patrick ; Ellis, Ian O. ; Green, Andrew R. ; Haider, Syed ; Brouilette, Kellie ; Saha, Antonio ; Vallath, Sabari ; Bowen, Rebecca ; Chelala, Claude ; Eccles, Diana ; Tapper, William J. ; Thompson, Alastair M. ; Quinlan, Phillip ; Jordan, Lee ; Gillett, Cheryl ; Brentnall, Adam ; Violette, Shelia ; Weinreb, Paul H. ; Kendrew, Jane ; Barry, Simon T. ; Hart, Ian R. ; Jones, J. Louise ; Marshall, John F. (2014)

BACKGROUND: <br/>Integrin ?v?6 promotes migration, invasion, and survival of cancer cells; however, the relevance and role of ?v?6 has yet to be elucidated in breast cancer.<br/><br/>METHODS: <br/>Protein expression of integrin subunit beta6 (?6) was measured in breast cancers by immunohistochemistry (n &gt; 2000) and ITGB6 mRNA expression measured in the Molecular Taxonomy of Breast Cancer International Consortium dataset. Overall survival was assessed using Kaplan Meier curves, and bioinformatics statistical analyses were performed (Cox proportional hazards model, Wald test, and Chi-square test of association). Using antibody (264RAD) blockade and siRNA knockdown of ?6 in breast cell lines, the role of ?v?6 in Human Epidermal Growth Factor Receptor 2 (HER2) biology (expression, proliferation, invasion, growth in vivo) was assessed by flow cytometry, MTT, Transwell invasion, proximity ligation assay, and xenografts (n ? 3), respectively. A student's t-test was used for two variables; three-plus variables used one-way analysis of variance with Bonferroni's Multiple Comparison Test. Xenograft growth was analyzed using linear mixed model analysis, followed by Wald testing and survival, analyzed using the Log-Rank test. All statistical tests were two sided.<br/><br/>RESULTS: <br/>High expression of either the mRNA or protein for the integrin subunit ?6 was associated with very poor survival (HR = 1.60, 95% CI = 1.19 to 2.15, P = .002) and increased metastases to distant sites. Co-expression of ?6 and HER2 was associated with worse prognosis (HR = 1.97, 95% CI = 1.16 to 3.35, P = .01). Monotherapy with 264RAD or trastuzumab slowed growth of MCF-7/HER2-18 and BT-474 xenografts similarly (P &lt; .001), but combining 264RAD with trastuzumab effectively stopped tumor growth, even in trastuzumab-resistant MCF-7/HER2-18 xenografts.<br/><br/>CONCLUSIONS: <br/>Targeting ?v?6 with 264RAD alone or in combination with trastuzumab may provide a novel therapy for treating high-risk and trastuzumab-resistant breast cancer patients.<br/>
  • References (34)
    34 references, page 1 of 4

    1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.

    2. Slamon DJ, Godolphin W, Jones LA, et  al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.

    3. Wong AL, Lee SC. Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer. 2012;2012:415170.

    4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.

    5. Romond EH, Perez EA, Bryant J, et  al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.

    6. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res. 2011;71(5):1515-1519.

    7. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263-275.

    8. Lindsley CW, Barnett SF, Layton ME, Bilodeau MT. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets. 2008;8(1):7-18.

    9. Ueda Y, Wang S, Dumont N, et  al. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor betainduced cell motility. J Biol Chem. 2004;279(24):505-513.

    10. Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 2006;66(19):9591-9600.

  • Metrics
    No metrics available